

Kenya

Population 2014

45 million

Estimates of TB burden * 2014	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	9.4 (6.7–12)	21 (15–28)
Mortality (HIV+TB only)	8.1 (6.4–10)	18 (14–22)
Prevalence (includes HIV+TB)	120 (64–190)	266 (142–427)
Incidence (includes HIV+TB)	110 (110–110)	246 (240–252)
Incidence (HIV+TB only)	40 (38–42)	89 (84–93)

Case detection, all forms (%)	80 (78–82)
-------------------------------	------------

Estimates of MDR-TB burden * 2014	New	Retreatment
% of TB cases with MDR-TB	2.2 (0.3–4.1)	14 (12–15)
MDR-TB cases among notified pulmonary TB cases	1 400 (200–2 700)	1 100 (930–1 200)

TB case notifications 2014	New **	Relapse
Pulmonary, bacteriologically confirmed	34 997	3 569
Pulmonary, clinically diagnosed	30 872	2 947
Extrapulmonary	14 640	1 000

Total new and relapse	88 025
Previously treated, excluding relapses	1 269
Total cases notified	89 294

Among 89 294 new and relapse cases:
8 448 (9%) cases aged under 15 years; male:female ratio: 1.5

Reported cases of RR-/MDR-TB 2014	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	17 619 (50%)	7 436 (85%)	23 865
Laboratory-confirmed RR-/MDR-TB cases			644
Patients started on MDR-TB treatment ***			544

TB/HIV 2014	Number	(%)
TB patients with known HIV status	84 423	(95)
HIV-positive TB patients	30 002	(36)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	29 735	(99)
HIV-positive TB patients on antiretroviral therapy (ART)	26 142	(87)
HIV-positive people screened for TB	426 102	
HIV-positive people provided with IPT		

Treatment success rate and cohort size	(%)	Cohort
New cases registered in 2013	(86)	81 255
Previously treated cases registered in 2013	(78)	8 445
HIV-positive TB cases, all types, registered in 2013	(79)	31 755
RR-/MDR-TB cases started on second-line treatment in 2012	(83)	197
XDR-TB cases started on second-line treatment in 2012		0

Laboratories 2014	
Smear (per 100 000 population)	4.3
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.3
Sites performing Xpert MTB/RIF	70
Is second-line drug susceptibility testing available?	No

Financing TB control 2015	
National TB programme budget (US\$ millions)	45
% Funded domestically	26%
% Funded internationally	28%
% Unfunded	45%


* Ranges represent uncertainty intervals

** Includes cases with unknown previous TB treatment history

*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


Tuberculosis profile

(Rate per 100 000 population per year)




■ Mortality (excludes HIV+TB)

(Rate per 100 000 population)




■ Prevalence

(Rate per 100 000 population per year)




■ Notified (new and relapse) ■ Incidence
■ Incidence (HIV+TB only)

(Number of patients)




■ HIV-positive TB patients
■ on CPT ■ on ART

Treatment success rate (%)



■ New ■ Retreatment
■ HIV-positive ■ RR-/MDR-TB ■ XDR-TB

Total budget (US\$ millions)



■ Funded domestically ■ Funded internationally
■ Unfunded